Add new comment

Given the market for Sheets, Harden, and Bedard (as reflected in the salaries they received), most teams do not think Bedard is going to pitch much this year, or at least not at his previously established level.
The only alternative view of the situation is that Bedard was so predisposed to coming to Seattle that no other team really had the capacity to drive up the price.
While I agree that the doctors know better than the uneducated masses, medicine is still a black art as much as a science populated by people predisposed to overvalue their worth.  Who among us hasn't had to endure the self-important arrogance of an MD?  
To summarize, its a good deal for the M's but I don't buy that Sheets and Harden are legitimate comparisons... and the variance in salary that the three received indicates that MLB teams don't see them as equivalent risks either.
The possibility exists that the M's are working with better information than any other team and therefore are able to better assess the risk.  Here's hoping that's the case!